NASDAQ:PBYI Puma Biotechnology (PBYI) Stock Price, News & Analysis $8.30 -0.23 (-2.70%) Closing price 04:00 PM EasternExtended Trading$8.30 0.00 (0.00%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Puma Biotechnology Stock (NASDAQ:PBYI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Puma Biotechnology alerts:Sign Up Key Stats Today's Range$8.14▼$8.5450-Day Range$6.81▼$8.5352-Week Range$3.03▼$8.66Volume461,513 shsAverage Volume351,465 shsMarket Capitalization$422.47 millionP/E Ratio17.29Dividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Puma Biotechnology, Inc. is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs. The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer. Nerlynx has since been explored in additional settings, including metastatic disease, reflecting Puma’s commitment to expanding therapeutic options for patients. Beyond its approved product, Puma Biotechnology maintains a clinical‐stage pipeline that includes additional oncology candidates and combination regimens under evaluation in multiple cancer indications. Through ongoing trials, the company aims to build on Nerlynx’s platform and bring new treatment options to patients facing aggressive tumors. Since completing its initial public offering on Nasdaq under the ticker PBYI in 2013, Puma has established commercial operations in the United States and forged partnerships to support product launches and regulatory filings in Europe and other global markets. Under the leadership of Founder and President/CEO Alan H. Auerbach, the company continues to leverage strategic collaborations and scientific expertise to drive its growth and development efforts.AI Generated. May Contain Errors. Read More Puma Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScorePBYI MarketRank™: Puma Biotechnology scored higher than 21% of companies evaluated by MarketBeat, and ranked 750th out of 840 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingPuma Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePuma Biotechnology has only been the subject of 1 research reports in the past 90 days.Read more about Puma Biotechnology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-60.71% Earnings GrowthEarnings for Puma Biotechnology are expected to decrease by -60.71% in the coming year, from $0.28 to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Puma Biotechnology is 17.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Puma Biotechnology is 17.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.16.Price to Book Value per Share RatioPuma Biotechnology has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Puma Biotechnology's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.16% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 8.47.Change versus previous monthShort interest in Puma Biotechnology has recently decreased by 1.90%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest1 people have searched for PBYI on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Puma Biotechnology to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,006,711.00 in company stock.Percentage Held by Insiders22.20% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Puma Biotechnology's insider trading history. Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBYI Stock News HeadlinesDouglas Hunt Sells 8,460 Shares of Puma Biotechnology (NASDAQ:PBYI) StockJuly 9, 2026 | insidertrades.comPuma Biotechnology Shareholders Back Governance, Reject Warrant ExtensionJune 16, 2026 | tipranks.comFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.July 20 at 1:00 AM | Porter & Company (Ad)Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 3, 2026 | businesswire.comPuma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft EarningsMay 14, 2026 | finance.yahoo.comEarnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00May 11, 2026 | finance.yahoo.comPuma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comPuma Biotech: Q1 Earnings SnapshotMay 8, 2026 | sfgate.comSee More Headlines PBYI Stock Analysis - Frequently Asked Questions How have PBYI shares performed this year? Puma Biotechnology's stock was trading at $5.95 at the start of the year. Since then, PBYI stock has increased by 38.6% and is now trading at $8.2490. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology, Inc. (NASDAQ:PBYI) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.09. The biopharmaceutical company earned $44.81 million during the quarter, compared to analyst estimates of $42 million. Puma Biotechnology had a net margin of 10.69% and a trailing twelve-month return on equity of 20.30%. Read the conference call transcript. Who are Puma Biotechnology's major shareholders? Top institutional shareholders of Puma Biotechnology include Baron Wealth Management LLC (0.07%). Insiders that own company stock include Alan H Auerbach, Douglas M Hunt, Maximo F Nougues, Brian M Stuglik, Jeffrey Jerome Ludwig, Alvin F Wong, Allison Dorval, Troy Edward Wilson, Jay M Moyes, Michael Patrick Miller, Alessandra Cesano and Adrian Senderowicz. View institutional ownership trends. How do I buy shares of Puma Biotechnology? Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Puma Biotechnology investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), First Solar (FSLR), Humana (HUM), American Water Works (AWK) and NVIDIA (NVDA). Company Calendar Last Earnings5/07/2026Today7/20/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (18m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 PBYI's financial health is in the Green zone, according to TradeSmith. PBYI has been in this zone for over 18 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PBYI CIK1401667 Webwww.pumabiotechnology.com Phone(424) 248-6500Fax424-248-6501Employees200Year Founded2010Profitability EPS (Trailing Twelve Months)$0.48 Trailing P/E Ratio17.29 Forward P/E Ratio29.64 P/E GrowthN/ANet Income$31.11 million Net Margins10.69% Pretax Margin12.80% Return on Equity20.30% Return on Assets12.05% Debt Debt-to-Equity RatioN/A Current Ratio2.38 Quick Ratio2.24 Sales & Book Value Annual Sales$228.40 million Price / Sales1.85 Cash Flow$0.81 per share Price / Cash Flow10.23 Book Value$2.59 per share Price / Book3.20Miscellaneous Outstanding Shares50,900,000Free Float39,599,000Market Cap$422.47 million OptionableOptionable Beta1.20 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PBYI) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...Chaikin Analytics | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredNVIDIA offered $40B. The answer was no.Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried ...Behind the Markets | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored#1 Power Grid Stock Right NowThe U.S. power grid is cracking - and one company's technology is already generating round-the-clock power in ...Altimetry | SponsoredTrump's Next Move Could Shrink Your DollarThere's a plan in Washington being called the 'Mar-a-Lago Accord' - a deliberate strategy to weaken the U.S. d...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
